Skip to main content
SpringerLink
Log in

Emergence of truly “Individualized” therapy: The poly (adenosine diphosphate-ribose) polymerase inhibitors

  • Clinical Trials Report
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dantzer F, de La Rubia G, Menissier-De Murcia J, et al.: Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1. Biochemistry 2000, 39:7559–7569.

    Article  CAS  PubMed  Google Scholar 

  2. Gudmundsdottir K, Ashworth A: The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006, 25:5864–5874.

    Article  CAS  PubMed  Google Scholar 

  3. Khanna KK, Jackson SP: DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001, 27:247–254.

    Article  CAS  PubMed  Google Scholar 

  4. Farmer H, McCabe N, Lord CJ, et al.: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917–921.

    Article  CAS  PubMed  Google Scholar 

  5. Bryant HE, Schultz N, Thomas HD, et al.: Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005, 434:913–917.

    Article  CAS  PubMed  Google Scholar 

  6. Fong PC, Boss DS, Carden CP, et al.: AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a phase I study [abstract 5510]. J Clin Oncol 2008, 26.

  7. Audeh MW, Penson RT, Friedlander M, et al.: Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer [abstract 5500]. J Clin Oncol 2009, 27.

  8. Edwards SL, Brough R, Lord CJ, et al.: Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 451:1111–1115.

    Article  CAS  PubMed  Google Scholar 

  9. Tan DS, Rothermundt C, Thomas K, et al.: “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 208, 26:5530–5536.

  10. O’shaughnessy J, Osborne C, Pippen J, et al.: Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial [abstract 3]. J Clin Oncol 2009, 27.

Download references

Author information

Authors and Affiliations

  1. Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA

    Robert L. Coleman

  2. PO Box 301439, Unit 1362, Houston, TX, 77230, USA

    Robert L. Coleman

Authors
  1. Robert L. Coleman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert L. Coleman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coleman, R.L. Emergence of truly “Individualized” therapy: The poly (adenosine diphosphate-ribose) polymerase inhibitors. Curr Oncol Rep 11, 414–416 (2009). https://doi.org/10.1007/s11912-009-0067-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-009-0067-6

Keywords

Search

Navigation